Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Brian Wolpin

Tracked across 2 events · 166 articles · First seen May 29, 2026 · Last active Aug 29, 2026

Sentiment
40
Attention
7
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
7 70
Tech
Impact: Brian Wolpin, from the Dana–Farber Cancer Institute, presented the findings of the daraxonrasib study and advocated for its adoption as a new standard of care.
May 29, 2026 · 74 articles
7 10
Regulatory
Impact: Brian Wolpin led the RASolute 302 trial and presented the results at ASCO, receiving a standing ovation. He called the drug a new standard of care for previously treated metastatic pancreatic cancer.
Aug 26, 2026 · 92 articles
ERGEN INTELLIGENCE
Track Brian Wolpin live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.